TidalSense raised $19 million to expand its AI-powered respiratory diagnostic platform across Europe and prepare for entry into the U.S. market. The Cambridge, UK-based company’s N-Tidal Diagnose system is designed to identify chronic obstructive pulmonary disease without traditional spirometry.
Patients breathe normally into a handheld device for 75 seconds, producing a carbon dioxide waveform that TidalSense’s AI models analyze for signs of COPD. The company says results are available in under five minutes, while healthcare professionals can be trained to use the device in about 10 minutes. Its models were trained on more than 2.5 million patient breaths.
For patients and clinicians, the platform could make COPD testing faster and more accessible in settings without specialist spirometry resources. TidalSense will use the funding to accelerate commercialization, support U.S. expansion and extend the platform to additional respiratory conditions, including asthma.
Image Credit: TidalSense
Key Themes Behind This Trend
- AI Respiratory Diagnostics
- Machine learning analysis of breath waveforms creates opportunities for faster, lower-resource detection of chronic lung conditions beyond specialist clinical settings.
- Handheld Breath Testing
- Compact diagnostic devices are reshaping respiratory care by replacing complex equipment with simple patient-friendly tools suited to primary care and community environments.
- Rapid Point-of-care Screening
- Near-instant test results open new pathways for earlier intervention, reduced referral bottlenecks and broader chronic disease monitoring outside hospital systems.
Where This Applies
- Digital Health
- AI-enabled diagnostic platforms are expanding the market for software-driven clinical tools that combine medical devices, data analytics and scalable care delivery.
- Medical Devices
- Portable respiratory hardware presents growth potential for device makers focused on accessible diagnostics, workflow efficiency and alternatives to legacy testing systems.
- Pulmonary Care
- Chronic respiratory disease management is being transformed by technologies that simplify diagnosis and support expansion into conditions such as COPD and asthma.
